- Home
- / CureVac
CureVac
Stock Price
$8
2023-09-15
Market Capitalization
$1.8 B
2023-09-15
Revenue
€67.4 M
FY, 2022
CureVac Summary
Company Summary
- Overview
- CureVac is a biotechnology company offering messenger RNA (mRNA) technology. It develops mRNA-based prophylactic vaccines addressing infectious diseases, RNA-based cancer immunotherapies, and molecular therapies.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Tübingen, DE | view all locations
- Website
- https://www.curevac.com/en/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Ingmar Hoerr, Co-Founder
Florian von der Mülbe, Chief Production Officer & Co-Founder
Pierre Kemula, Chief Financial Officer
Operating MetricsView all
Patent Applications
500
Mar, 2020
Pre-Clinical Discovery Phase Products
17
183.3%
Jun, 2023
Pre-Clinical Development Phase Products
7
Jun, 2023
LocationsView all
6 locations detected
Tübingen, BW HQ
Germany
Friedrich-Miescher-Straße 15
Boston, MA
United States
250 Summer St 3rd Fl
Ottignies-Louvain-la-Neuve, Région Wallonne
Belgium
Av. Jean Monnet 4
Wiesbaden, HE
Germany
Leipziger Str. 35
Amsterdam, NH
Netherlands
Science Park 106
Basel, BS
Switzerland
Wartenbergstrasse 40
CureVac Financials
Summary Financials
- Revenue (Q2, 2023)
- €7.6M
- Gross profit (Q2, 2023)
- (€12.0M)
- Net income (Q2, 2023)
- (€67.4M)
- Cash (Q2, 2023)
- €537.9M
- EBIT (Q2, 2023)
- (€72.0M)
- Enterprise value
- $1.3B